

DR REDDYS LABORATORIES LTD  
Form 6-K  
October 11, 2016

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13A-16 OR 15D-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**September 2016**

**Commission File Number 1-15182**

**DR. REDDY S LABORATORIES LIMITED**

**(Translation of registrant s name into English)**

**8-2-337, Road No. 3, Banjara Hills**

**Hyderabad, Telangana 500 034, India**

**+91-40-49002900**

**(Address of principal executive office)**

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's home country), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-

**EXHIBITS**

Exhibit Number	Description of Exhibits
99.1	Press Release, Dr. Reddy's announces Purple Health, a unique patient-centric platform that takes care beyond the pill, September 1, 2016.
99.2	Press Release, Dr. Reddy's Laboratories announces the launch of Bupropion HCl Extended-Release Tablets, USP (SR) in the U.S. Market, September 2, 2016.
99.3	Press Release, Dr. Reddy's listed on Dow Jones Sustainability Indices 2016, September 13, 2016.
99.4	Press Release, Dr. Reddy's Expands Strategic Collaboration with Amgen in India, September 16, 2016.
99.5	Press Release, Dr. Reddy's Laboratories announces the launch of Paricalcitol Injection in the U.S. Market, September 19, 2016.
99.6	Press Release, Leading global pharmaceutical company, Dr. Reddy's Laboratories now in Colombia, October 7, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DR. REDDY S LABORATORIES LIMITED

(Registrant)

Date: October 11, 2016

By: /s/ Sandeep Poddar

Name: Sandeep Poddar

Title: Company Secretary